Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matilde Inglese

Showing results (301-310 of 315) with videos related to

Pageof 32
Sort By:
Neurology|May 30, 2014
Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin, Stephen C Reingold, Jeffrey A Cohen, et al.
Ebiomedicine|May 8, 2022
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in ItalyMaria Pia Sormani, Irene Schiavetti, Matilde Inglese, et al.
Multiple Sclerosis and Related Disorders|October 26, 2022
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Irene Schiavetti, Roberto Bergamaschi, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Journal of Neurology|March 10, 2026
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMSTommaso Guerra, Giuseppe Lucisano, Maria A Rocca, et al.
CNS Drugs|January 28, 2026
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter StudyGianmarco Abbadessa, Damiano Marastoni, Floriana Bile, et al.
Brain : a Journal of Neurology|December 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosisGéraldine Androdias, Jan D Lünemann, Elisabeth Maillart, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2026
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|April 2, 2024
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sexNaila Makhani, Christine Lebrun-Frenay, Aksel Siva, et al.
Journal of Neurology|April 3, 2024
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosisElisabetta Maida, Marcello Moccia, Raffaele Palladino, et al.
Pageof 32

Showing results (301-310 of 315) with videos related to

Sort By:
Pageof 32
Neurology|May 30, 2014
Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin, Stephen C Reingold, Jeffrey A Cohen, et al.
Ebiomedicine|May 8, 2022
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in ItalyMaria Pia Sormani, Irene Schiavetti, Matilde Inglese, et al.
Multiple Sclerosis and Related Disorders|October 26, 2022
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Irene Schiavetti, Roberto Bergamaschi, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Journal of Neurology|March 10, 2026
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMSTommaso Guerra, Giuseppe Lucisano, Maria A Rocca, et al.
CNS Drugs|January 28, 2026
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter StudyGianmarco Abbadessa, Damiano Marastoni, Floriana Bile, et al.
Brain : a Journal of Neurology|December 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosisGéraldine Androdias, Jan D Lünemann, Elisabeth Maillart, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2026
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|April 2, 2024
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sexNaila Makhani, Christine Lebrun-Frenay, Aksel Siva, et al.
Journal of Neurology|April 3, 2024
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosisElisabetta Maida, Marcello Moccia, Raffaele Palladino, et al.
Pageof 32